FDA Approves Pfizer's Braftovi Plus Cetuximab for Colorectal Cancer with BRAF Mutations

The U.S. Food and Drug Administration (FDA) approved Pfizer’s Braftovi (encorafenib) in combination with cetuximab (Erbitux) for adults with metastatic colorectal cancer (CRC) with a BRAFV600E mutation. The mutation is identified with an FDA-approved companion diagnostic, and the indication is for after previous therapy.